Cargando…

Clinical use and applications of histone deacetylase inhibitors in multiple myeloma

The incorporation of various novel therapies has resulted in a significant survival benefit in newly diagnosed and relapsed patients with multiple myeloma (MM) over the past decade. Despite these advances, resistance to therapy leads to eventual relapse and fatal outcomes in the vast majority of pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tandon, Nidhi, Ramakrishnan, Vijay, Kumar, Shaji K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866749/ https://www.ncbi.nlm.nih.gov/pubmed/27226735 http://dx.doi.org/10.2147/CPAA.S94021

Ejemplares similares

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma
por: Ramakrishnan, Vijay G., et al.
Publicado: (2019)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
por: Chhabra, Saurabh
Publicado: (2017)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
por: Hideshima, T, et al.
Publicado: (2015)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
por: Redic, Kimberly A, et al.
Publicado: (2016)

Inhibitor of Apoptosis Proteins (IAPs) as therapeutic targets in Multiple Myeloma (MM)
por: Ramakrishnan, Vijay, et al.
Publicado: (2014)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Interpreting clinical assays for histone deacetylase inhibitors
por: Martinet, Nadine, et al.
Publicado: (2011)

Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma
por: Okabe, Seiichi, et al.
Publicado: (2021)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Histone deacetylase inhibitors: clinical implications for hematological malignancies
por: Tambaro, Francesco Paolo, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

Potential use of histone deacetylase inhibitors in cancer therapy
por: Gołąbek, Karolina, et al.
Publicado: (2015)

Efficacy and toxicity of histone deacetylase inhibitors in relapsed/refractory multiple myeloma: Systematic review and meta-analysis of clinical trials
por: Gao, Xiao, et al.
Publicado: (2019)

Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy
por: He, Yanjuan, et al.
Publicado: (2021)

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)

The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2018)

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
por: Bishton, Mark J., et al.
Publicado: (2010)

Dual Inhibitors Against Topoisomerases and Histone Deacetylases
por: Seo, Young Ho
Publicado: (2015)

Histone Deacetylase Inhibitors and Diabetic Kidney Disease
por: Hadden, Mitchell J., et al.
Publicado: (2018)

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
por: Verza, Flávia Alves, et al.
Publicado: (2020)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022)

Histone Deacetylase Inhibitors from Marine Invertebrates
por: Luparello, Claudio, et al.
Publicado: (2020)

The Impact of Fluorination on the Design of Histone Deacetylase Inhibitors
por: Tien Anh, Duong, et al.
Publicado: (2023)

Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton
por: Mithraprabhu, S, et al.
Publicado: (2014)

Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
por: Maneix, Laure, et al.
Publicado: (2022)

Regulation of Immune Responses by Histone Deacetylase Inhibitors
por: Licciardi, Paul V., et al.
Publicado: (2012)

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
por: Stintzing, Sebastian, et al.
Publicado: (2011)

Zinc binding groups for histone deacetylase inhibitors
por: Zhang, Lei, et al.
Publicado: (2018)

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
por: Tan, Jiahuai, et al.
Publicado: (2010)

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
por: Wagner, Julia M., et al.
Publicado: (2010)

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer
por: Cang, Shundong, et al.
Publicado: (2009)

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
por: Mottamal, Madhusoodanan, et al.
Publicado: (2015)

Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma
por: Cheriyath, V, et al.
Publicado: (2011)

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_osou12ed0aqp77fion0hl9ut74